

October 5, 2019

To,
**SINGAPORE EXCHANGE SECURITIES
TRADING LIMITED**
11 North Buona Vista Drive,
#06-07 The Metropolis Tower 2,
Singapore – 138589

Dear Sir,

Sub: Update on the USFDA inspection of Glenmark's Baddi manufacturing facility in Himachal Pradesh

We would like to inform you that in relation to an inspection conducted by the USFDA between April 15, 2019 to April 20, 2019 at the company's Baddi facility in Himachal Pradesh, India, the company had earlier informed that the inspection was classified as an "Official Action Indicated" vide a letter by the USFDA. With regards to the same inspection, the USFDA has now issued a "Warning Letter" to the Baddi facility. The company is committed to work along with the USFDA to implement all the necessary corrective actions required to address the concerns raised in the letter and is in the process of preparing a detailed response to the USFDA within 15 working days.

We believe that the existing manufacturing and the sale of products from this facility will not be impacted. The Baddi facility is expected to contribute USD 30mn in total sales for this financial year which is approximately 7% of the total US sales. There are no major pending approvals from this facility in the next 12 months. There will be no financial impact on the organisation on account of this development.

Glenmark currently has eight manufacturing facilities approved by the USFDA – five formulations facilities and three API facilities under Glenmark Life Sciences Limited. None of these facilities except Baddi has any outstanding issues with the USFDA at this point in time.

This is for your information and record please.

Thanking you,

Yours faithfully,
For Glenmark Pharmaceuticals Limited

HARISH
VINAYAK
KUBER

Digitally signed by
HARISH VINAYAK KUBER
Date: 2019.10.05 11:37:28
+05'30'

Harish Kuber
Company Secretary & Compliance Officer

Glenmark Pharmaceuticals Ltd.

Glenmark House, B D Sawant Marg, Andheri (E), Mumbai 400 099

T: 91 22 4018 9999 F: 91 22 4018 9988 CIN No: L24299MH1977PLC019982 W: www.glenmarkpharma.com

Registered office: B/2, Mahalaxmi Chambers, 22 Bhulabhai Desai Road, Mumbai 400 026 E: complianceofficer@glenmarkpharma.com